{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:22:22Z","timestamp":1783041742850,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Yildiz Technical University Scientific Research Project Coordination Department","award":["FBA-2018-3359"],"award-info":[{"award-number":["FBA-2018-3359"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to generate antibodies against the whole-cell lysate of the AU-565 breast cancer cell line using hybridoma technology and to assess their immunogenic properties and preliminary immunoassay-oriented reactivity. Two adjuvants, Complete Freund\u2019s Adjuvant (CFA) and Polyoxidonium (PO), were compared for their ability to enhance immune responses. Cytokine profiling was also performed to evaluate the immunomodulatory effects of antigen\u2013adjuvant formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AU-565 cell lysates were prepared by sonication and combined with CFA or PO. Immunostimulatory activity was evaluated in vitro by nitric oxide (NO) production in J774 macrophages and in vivo by antibody titers in Balb\/c mice. Hybridoma cells were generated from splenocytes of immunized mice. Since single-cell cloning was not performed, antibodies were collected from pooled hybridoma cultures, representing a mixture of monoclonal antibodies recognizing multiple epitopes. Cytokine levels (IL-6, IL-12, GM-CSF, and TNF-\u03b1) were quantified by ELISA to characterize the inflammatory response pattern induced by the antigen\u2013adjuvant formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The AU-565 antigen\u2009+\u2009CFA formulation significantly increased NO production compared with untreated control macrophages and generated the strongest antibody titers compared with the PBS control group. Cytokine profiling showed that the AU-565 antigen\u2009+\u2009CFA formulation significantly increased IL-12, GM-CSF, and TNF-\u03b1 secretion compared with untreated control macrophages, indicating a pronounced pro-inflammatory response pattern in the macrophage model, while a moderate IL-6 increase relative to untreated control macrophages suggested partial support for humoral-associated signaling. The hybridoma-derived antibody mixture displayed stronger ELISA reactivity toward AU-565 and MCF-7 lysates than the commercial antibody, indicating broader relative lysate recognition under the assay conditions used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The hybridoma-derived antibody mixture showed strong immunogenicity, cytokine-associated immune stimulation, and preliminary potential for breast cancer-oriented immunoassay development; however, additional validation of specificity and analytical performance is required before diagnostic utility can be concluded. The AU-565 antigen\u2013CFA combination not only enhanced antibody production but also promoted a favorable cytokine profile, underscoring CFA\u2019s superiority as an adjuvant in breast cancer-oriented immunogen design.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16143-7","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:03:13Z","timestamp":1778306593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating immunoreactivity of hybridoma-derived antibody mixtures generated against AU-565 cell line for diagnosis and immunotherapy of breast cancer"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-5638","authenticated-orcid":false,"given":"Murat","family":"Ihlamur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-6194","authenticated-orcid":false,"given":"At\u0131fcan","family":"Demi\u0307rci\u0307o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-9890","authenticated-orcid":false,"given":"Asl\u0131 P\u0131nar","family":"Zorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-4528","authenticated-orcid":false,"given":"Emrah \u015eefik","family":"Abamor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6018-832X","authenticated-orcid":false,"given":"Melahat","family":"Ba\u011f\u0131rova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7031-5986","authenticated-orcid":false,"given":"Adil","family":"Allahverdi\u0307yev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"16143_CR1","doi-asserted-by":"crossref","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287.","DOI":"10.3390\/cancers13174287"},{"issue":"3","key":"16143_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cpet.2018.02.006","volume":"13","author":"TA Moo","year":"2018","unstructured":"Moo TA, Sanford R, Dang C, Morrow M. Overview of Breast Cancer Therapy. PET Clin. 2018;13(3):339\u201354.","journal-title":"PET Clin"},{"issue":"3","key":"16143_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.52547\/ibj.25.3.140","volume":"25","author":"M Simonian","year":"2021","unstructured":"Simonian M, Haji Ghaffari M, Negahdari B. Immunotherapy for Breast Cancer Treatment. Iran Biomed J. 2021;25(3):140\u201356.","journal-title":"Iran Biomed J"},{"key":"16143_CR4","doi-asserted-by":"crossref","unstructured":"Duffy SW, Tab\u00e1r L, Yen AM, Dean PB, Smith RA, Jonsson H, T\u00f6rnberg S, Chen SL, Chiu SY, Fann JC, Ku MM, Wu WY, Hsu CY, Chen YC, Svane G, Azavedo E, Grundstr\u00f6m H, Sund\u00e9n P, Leifland K, Frodis E, et al. Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women. Cancer. 2020;126(13):2971\u20139.","DOI":"10.1002\/cncr.32859"},{"issue":"Suppl 2","key":"16143_CR5","first-page":"17","volume":"9","author":"MI Nounou","year":"2015","unstructured":"Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies. Breast Cancer (Auckl). 2015;9(Suppl 2):17\u201334.","journal-title":"Breast Cancer (Auckl)"},{"issue":"1","key":"16143_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13058-025-02038-1","volume":"27","author":"AM Cheung","year":"2025","unstructured":"Cheung AM, Wang D, Quintayo MA, Yerofeyeva Y, Spears M, Bartlett JMS, Stein L, Bayani J, Yaffe MJ. Intra-tumoral spatial heterogeneity in breast cancer quantified using high-dimensional protein multiplexing and single cell phenotyping. Breast Cancer Res. 2025;27(1):88.","journal-title":"Breast Cancer Res"},{"issue":"16","key":"16143_CR7","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.3390\/cancers15164164","volume":"15","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Jiang L, Ding X. Advancing Breast Cancer Heterogeneity Analysis: Insights from Genomics, Transcriptomics and Proteomics at Bulk and Single-Cell Levels. Cancers. 2023;15(16):4164.","journal-title":"Cancers"},{"issue":"3","key":"16143_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2144\/btn-2018-0065","volume":"65","author":"CA Ascoli","year":"2018","unstructured":"Ascoli CA, Aggeler B. Overlooked benefits of using polyclonal antibodies. Biotechniques. 2018;65(3):127\u201336.","journal-title":"Biotechniques"},{"key":"16143_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.crimmu.2021.03.002","volume":"2","author":"JZ Moraes","year":"2021","unstructured":"Moraes JZ, Hamaguchi B, Braggion C, Speciale ER, Cesar FBV, Soares GdFdS, Osaki JH, Pereira TM, Aguiar RB. Hybridoma technology: is it still useful? Curr Res Immunol. 2021;2:32\u201340.","journal-title":"Curr Res Immunol"},{"issue":"1","key":"16143_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41598-020-58571-w","volume":"10","author":"M Listek","year":"2020","unstructured":"Listek M, H\u00f6now A, Gossen M, Hanack K. A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line. Sci Rep. 2020;10(1):1664.","journal-title":"Sci Rep"},{"issue":"10","key":"16143_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","volume":"21","author":"SC Oostindie","year":"2022","unstructured":"Oostindie SC, Lazar GA, Schuurman J, Parren P. Avidity in antibody effector functions and biotherapeutic drug design. Nat Rev Drug Discov. 2022;21(10):715\u201335.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"16143_CR12","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1111\/bph.13450","volume":"173","author":"S Carvalho","year":"2016","unstructured":"Carvalho S, Levi-Schaffer F, Sela M, Yarden Y. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol. 2016;173(9):1407\u201324.","journal-title":"Br J Pharmacol"},{"key":"16143_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","volume":"294\u2013295","author":"S Narote","year":"2025","unstructured":"Narote S, Desai SA, Patel VP, Deshmukh R, Raut N, Dapse S. Identification of new immune target and signaling for cancer immunotherapy. Cancer Genet. 2025;294\u2013295:57\u201375.","journal-title":"Cancer Genet"},{"issue":"9","key":"16143_CR14","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","volume":"13","author":"Y Sun","year":"2023","unstructured":"Sun Y, Yu X, Wang X, Yuan K, Wang G, Hu L, Zhang G, Pei W, Wang L, Sun C, et al. Bispecific antibodies in cancer therapy: Target selection and regulatory requirements. Acta Pharm Sin B. 2023;13(9):3583\u201397.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"16143_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/14760584.2019.1604231","volume":"18","author":"I Sarkar","year":"2019","unstructured":"Sarkar I, van Garg R, Drunen Littel-van den, Hurk S. Selection of adjuvants for vaccines targeting specific pathogens. Expert Rev Vaccines. 2019;18(5):505\u201321.","journal-title":"Expert Rev Vaccines"},{"issue":"13","key":"16143_CR16","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.vaccine.2018.02.071","volume":"36","author":"A Nouri","year":"2018","unstructured":"Nouri A, Nait Mohamed FA, Laraba-Djebari F. New and safe formulation for scorpion immunotherapy: Comparative study between saponin and FCA adjuvants associated to attenuated venom. Vaccine. 2018;36(13):1720\u20137.","journal-title":"Vaccine"},{"issue":"15","key":"16143_CR17","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1016\/j.vaccine.2005.10.046","volume":"24","author":"J Oscherwitz","year":"2006","unstructured":"Oscherwitz J, Hankenson FC, Yu F, Cease KB. Low-dose intraperitoneal Freund\u2019s adjuvant: toxicity and immunogenicity in mice using an immunogen targeting amyloid-beta peptide. Vaccine. 2006;24(15):3018\u201325.","journal-title":"Vaccine"},{"key":"16143_CR18","doi-asserted-by":"crossref","unstructured":"Kelleci K, Allahverdiyev A, Ba\u011firova M, Ihlamur M, Abamor E\u015e. Particulate and non-particle adjuvants in Leishmaniasis vaccine designs: a review. J Vector Borne Dis. 2023;60(2):125-141.","DOI":"10.4103\/0972-9062.361179"},{"key":"16143_CR19","doi-asserted-by":"publisher","first-page":"111902","DOI":"10.1016\/j.jphotobiol.2020.111902","volume":"208","author":"S Dinparvar","year":"2020","unstructured":"Dinparvar S, Bagirova M, Allahverdiyev AM, Abamor ES, Safarov T, Aydogdu M, Aktas D. A nanotechnology-based new approach in the treatment of breast cancer: Biosynthesized silver nanoparticles using Cuminum cyminum L. seed extract. J Photochem Photobiol B. 2020;208:111902.","journal-title":"J Photochem Photobiol B"},{"issue":"3","key":"16143_CR20","doi-asserted-by":"publisher","first-page":"035001","DOI":"10.1088\/2399-1984\/acde26","volume":"7","author":"S Dinparvar","year":"2023","unstructured":"Dinparvar S, Abamor ES, Oztav S, Inci TG, Ihlamur M, Baghirova M, Turgut-Balik D, Allahverdiyev AM. Evaluation of in vitro immunostimulatory and cytotoxic effects of recombinant survivin protein in combination with doxorubicin and breast cancer antigen-loaded polycaprolactone nanoparticles. Nano Futures. 2023;7(3):035001.","journal-title":"Nano Futures"},{"issue":"1","key":"16143_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0003-2697(82)90118-X","volume":"126","author":"LC Green","year":"1982","unstructured":"Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15\u00a0N]nitrate in biological fluids. Anal Biochem. 1982;126(1):131\u20138.","journal-title":"Anal Biochem"},{"issue":"1","key":"16143_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1):55\u201363.","journal-title":"J Immunol Methods"},{"key":"16143_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","volume":"5","author":"G Arango Duque","year":"2014","unstructured":"Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491.","journal-title":"Front Immunol"},{"key":"16143_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/ITT.S262566","volume":"9","author":"KMC Lee","year":"2020","unstructured":"Lee KMC, Achuthan AA, Hamilton JA. GM-CSF: A Promising Target in Inflammation and Autoimmunity. Immunotargets Ther. 2020;9:225\u201340.","journal-title":"Immunotargets Ther"},{"key":"16143_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","volume":"55","author":"BE Jones","year":"2018","unstructured":"Jones BE, Maerz MD, Buckner JH. IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol. 2018;55:9\u201314.","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"16143_CR26","doi-asserted-by":"publisher","first-page":"100297","DOI":"10.1101\/pdb.prot100297","volume":"2020","author":"EA Greenfield","year":"2020","unstructured":"Greenfield EA. Standard Immunization of Mice, Rats, and Hamsters. Cold Spring Harb Protoc. 2020;2020(3):100297.","journal-title":"Cold Spring Harb Protoc"},{"issue":"4","key":"16143_CR27","first-page":"506","volume":"17","author":"AP Zorba Yildiz","year":"2022","unstructured":"Zorba Yildiz AP, Koken GY, Abamor ES, Bag\u0131rova M, Tosyali OA, Kocagoz T, Allahverdiyev A. Polymeric Approach to Adjuvant System in Antibody Production against Leishmaniasis Based on Hybridoma Technology. Iran J Parasitol. 2022;17(4):506\u201316.","journal-title":"Iran J Parasitol"},{"key":"16143_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clinbiochem.2020.01.009","volume":"78","author":"S Jeong","year":"2020","unstructured":"Jeong S, Park M-J, Song W, Kim H-S. Current immunoassay methods and their applications to clinically used biomarkers of breast cancer. Clin Biochem. 2020;78:43\u201357.","journal-title":"Clin Biochem"},{"issue":"6","key":"16143_CR29","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1189\/jlb.1010550","volume":"89","author":"DA Wink","year":"2011","unstructured":"Wink DA, Hines HB, Cheng RYS, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol. 2011;89(6):873\u201391.","journal-title":"J Leukoc Biol"},{"key":"16143_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fcimb.2016.00152","volume":"6","author":"I Golovliov","year":"2016","unstructured":"Golovliov I, Lindgren H, Enesl\u00e4tt K, Conlan W, Mosnier A, Henry T, Sj\u00f6stedt A. An In Vitro Co-culture Mouse Model Demonstrates Efficient Vaccine-Mediated Control of Francisella tularensis SCHU S4 and Identifies Nitric Oxide as a Predictor of Efficacy. Front Cell Infect Microbiol. 2016;6:152.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"16143_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-023-01557-7","volume":"8","author":"T Zhao","year":"2023","unstructured":"Zhao T, Cai Y, Jiang Y, He X, Wei Y, Yu Y, Tian X. Vaccine adjuvants: mechanisms and platforms. Signal Transduct Target Therapy. 2023;8(1):283.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"16143_CR32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/biomedicines14010088","volume":"14","author":"M Ihlamur","year":"2026","unstructured":"Ihlamur M, Pelit Aray\u0131c\u0131 P, Abamor E\u015e. Poly(\u03b5-caprolactone) Nanoparticle Tumor-Lysate Vaccination in Mice Generates Hybridoma-Derived Antibodies Enabling Breast Cancer Diagnosis and Chemotherapy Synergy. Biomedicines. 2026;14(1):88.","journal-title":"Biomedicines"},{"issue":"3","key":"16143_CR33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10549-021-06459-2","volume":"191","author":"ML Disis","year":"2022","unstructured":"Disis ML, Cecil DL. Breast cancer vaccines for treatment and prevention. Breast Cancer Res Treat. 2022;191(3):481\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"16143_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.","journal-title":"J Hematol Oncol"},{"key":"16143_CR35","doi-asserted-by":"crossref","unstructured":"Kaczmarek M, Pozna\u0144ska J, Fechner F, Michalska N, Paszkowska S, Napiera\u0142a A, Mackiewicz A. Cancer vaccine therapeutics: limitations and effectiveness-a literature review. Cells. 2023;12(17):2159.","DOI":"10.3390\/cells12172159"},{"key":"16143_CR36","doi-asserted-by":"crossref","unstructured":"Nordin ML, Azemi AK, Nordin AH, Nabgan W, Ng PY, Yusoff K, Abu N, Lim KP, Zakaria ZA, Ismail N et al. Peptide-based vaccine against breast cancer: recent advances and prospects. Pharmaceuticals (Basel). 2023;16(7):923.","DOI":"10.3390\/ph16070923"},{"issue":"11","key":"16143_CR37","first-page":"2661","volume":"6","author":"S Zazo","year":"2016","unstructured":"Zazo S, Gonz\u00e1lez-Alonso P, Mart\u00edn-Aparicio E, Chamizo C, Crist\u00f3bal I, Arp\u00ed O, Rovira A, Albanell J, Eroles P, Lluch A, et al. Generation, characterization, and maintenance of trastuzumab-resistant HER2\u2009+\u2009breast cancer cell lines. Am J Cancer Res. 2016;6(11):2661\u201378.","journal-title":"Am J Cancer Res"},{"key":"16143_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/117822341000400004","volume":"4","author":"K Subik","year":"2010","unstructured":"Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG, et al. The Expression Patterns of ER, PR, HER2, CK5\/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl). 2010;4:35\u201341.","journal-title":"Breast Cancer (Auckl)"},{"key":"16143_CR39","doi-asserted-by":"crossref","unstructured":"Fatima GN, Fatma H, Saraf SK. Vaccines in breast cancer: challenges and breakthroughs. Diagnostics (Basel). 2023;13(13):2175.","DOI":"10.3390\/diagnostics13132175"},{"key":"16143_CR40","doi-asserted-by":"crossref","unstructured":"Donninger H, Li C, Eaton JW, Yaddanapudi K. Cancer vaccines: promising therapeutics or an unattainable dream. Vaccines (Basel). 2021;9(6):668.","DOI":"10.3390\/vaccines9060668"},{"issue":"1","key":"16143_CR41","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","volume":"8","author":"T Fan","year":"2023","unstructured":"Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Therapy. 2023;8(1):450.","journal-title":"Signal Transduct Target Therapy"},{"issue":"4","key":"16143_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/intimm\/dxg049","volume":"15","author":"DH Cribbs","year":"2003","unstructured":"Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petrushina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003;15(4):505\u201314.","journal-title":"Int Immunol"},{"issue":"12","key":"16143_CR43","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.20892\/j.issn.2095-3941.2023.0222","volume":"20","author":"JF Rossi","year":"2024","unstructured":"Rossi JF, Frayssinet P, Matciyak M, Tupitsyn N. Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer. Cancer Biol Med. 2024;20(12):1021\u201334.","journal-title":"Cancer Biol Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16143-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16143-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:11:10Z","timestamp":1783041070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16143-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16143"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16143-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Istanbul Bezm-i Alem University Experimental Animals Ethics Committee (ethics committee no. 2018.05).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"811"}}